Tiziana Life Sciences Share Discussion Threads

[andrbea] 01/5/2015 14:38

in the sector of cdk's, a peer comapny:

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) quarterly performance is 45.74%. On 20 April, Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, the Company’s second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor as a targeted anti-cancer agent.

[andrbea] 30/4/2015 19:04

chart says next step 110-115 and soonish

[wageslave] 21/4/2015 13:01

The recent fund raise does make the company a more interesting proposition, based on a steadier footing. This should bolster the share price in the medium to long term as it provides sufficient funding to see products through the the next stage by which time a larger partner may come on the scene imo.

[andrbea] 16/4/2015 13:44

more about that peer drug Ibrance

This makes Ibrance the first CDK 4/6 inhibitor to be approved by the FDA. Approval came more than two months ahead of schedule. Pfizer’s shares were up 1.2% on the news.

The accelerated approval was based on positive data from the phase II PALOMA-1 study. Results from the study revealed that a combination treatment of Ibrance and Femara led to a statistically significant improvement in progression-free survival (20.2 months) versus Femara alone (10.2 months).

[andrbea] 15/4/2015 14:31

tils are researching CDKs

seems to be a pretty hot field, just now.
cf

Developed by Pfizer Inc. (PFE: Quote), Ibrance works by inhibiting molecules, known as cyclin-dependent kinases (CDKs) 4 and 6, involved in promoting the growth of cancer cells. This drug is the first CDK 4/6 inhibitor to be approved by the FDA, and is available to order through select specialty pharmacies.

[jpuff] 14/4/2015 09:50

The red trades are my bed and ISA not sells folk!

[andrbea] 13/4/2015 18:36

cottoner
12 Apr'15 - 13:30 - 1009 of 1010 1 0

Snippet from Luke Johnson's article in today's Sunday Times


Giant drug makers are paying insane prices for biotech firms because they appear to have lost the ingenuity and confidence to discover new drugs themselves.

[hedgehog 100] 11/4/2015 16:23

Please note the following thread which may be of interest:

"THE REVERSE TAKEOVERS & SHELLS THREAD (RTO)"

[andrbea] 28/3/2015 08:46

Tils' research is centered around CDKs (see paragraph 2 of above translation).

the pharma majors are also active, of course, in the CDK space

see this recent article (Feb 2015) about Pfizer (billions mentioned):

/.....
Ibrance is expected to cost around $9,850 per month, bringing the cost of a 17-month regimen to around $167,000. Leerink analyst Seamus Fernandez projected 2015 sales of around $150 million in a Wednesday research note and consensus estimates put peak sales at about $3.8 billion by 2020. Fernandez noted that his team sees a potential for an additional $10 billion market opportunity if Ibrance were to land indications for high-risk early-stage breast cancer and recurrent cancer.

The drug's approval shores up plans for what could become a standalone unit of Pfizer. The drugmaker has talked about splitting up after having financials for each potential unit on hand after 2017, and the drug is considered a cornerstone product for the venture.

[jpuff] 20/3/2015 15:48

Has a good feel as I said in earlier post. Illiquid I agree and low free float

[sos100] 20/3/2015 15:40

whatever might be wrong it's certainly not the share price i still have a very small amount from last year.

this looks to be heading to towards £1,any small pull backs and buyers are just picking up the limited stock.

best thing it's a nice quiet thread so clearly under the radar. few % increases is fine by me,just wish i held on to more of the shares i had last year..

[jpuff] 20/3/2015 15:32

It says 840GBP do it's right! There are not many of these shares in free circulation it would seem.

[pranchalee] 20/3/2015 07:11

28000 at 3p gets u 840000k somthing not right

[jpuff] 16/3/2015 10:32

Hello Andrea, thank you for that and I do hope you are right! I have a good feeling too :)

[andrbea] 15/3/2015 13:01

welcome aboard Jpuff

quiet board, but a stock that's going places!

[jpuff] 15/3/2015 10:06

Bought a few, hello everyone :)

[andrbea] 10/3/2015 18:47

Bloomberg says: Next Earnings Announcement 03/31/2015

[andrbea] 25/2/2015 12:20

Jan 16 2015

Project outlook

The lead programme at Tiziana is about Bcl-3. Their research team is directly attributed with the discovery that Bcl-3 has a prominent role in the metastasis of mammary cancers. The group identified the B-cell Lymphoma 3 (Bcl-3) gene as a potential drug target to halt cancer metastasis, where malignant tumours spread to other parts of the body, a process typically associated with poor patient prognosis. Results showed suppressing this gene reduced the spread of cancer by more than 80%, from Dr Richard Clarkson at the University’s European Cancer Stem Cell Research Institute. Tiziana has also determined that Bcl-3 inhibition suppresses cell motility in triple-negative, HER-2-positive PR- and ER-positive breast cancer sub-types, suggesting that Bcl-3 may be a master regulator of this metastatic property not only in the more aggressive breast cancers, but across the whole clinical spectrum of breast disease (metastatic breast cancer, which affects up to 12,000 people annually in the UK). TPL entered into an agreement with the European Cancer Stem Cell Institute for the exclusive worldwide licence to any compound with potential therapeutic application against Bcl-3.

An initial lead molecule that has the ability to significantly block the activity of Bcl-3 has been identified (results not released), and Tiziana’s research team is focused on the discovery of further proprietary Bcl-3 inhibitor molecules with improved profiles that are suitable for development as a drug.

Ongoing pre-clinical studies on similar inhibitor compounds, scheduled for completion in 2014, are expected to determine if there is a significant improvement in survival in targeted animal models with existing advanced metastatic disease. If successful, the subsequent selection of a clinical candidate will initiate the process of manufacturing scale-up and pre-clinical toxicology and could lead to an Investigational New Drug (IND) application being made in 2016. Pre-clinical results will draw lots attention to determine their price.

[andrbea] 25/2/2015 12:18

Feb 10 2015

One investor backing breast cancer drug research at Cardiff University is an Italian businessman who has a personal as well as commercial interest.

Gabriele Cerrone has founded Tiziana Life Sciences, named after his late partner, who died three years ago of triple negative breast cancer.

[impala391] 14/2/2015 09:24

Nice move up, thought it was going down lol.
A bit of good needed news about the candidate for phase I plus the other two phase 11/111
Trials puts us in a good position